Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology

Systemic Therapies: CSF1R Inhibitors for Unresectable TGCT

At a Glance

Systemic therapies called CSF1R inhibitors, such as pexidartinib and vimseltinib, are used for TGCT when surgery is no longer a safe option. These targeted medications aim to shrink tumors, relieve pain, and prevent severe joint damage, though they are generally not a permanent cure.

When surgery is no longer the best option—either because the tumor has returned multiple times, is too large to remove safely, or would require a procedure that causes permanent disability—doctors turn to systemic therapies [1][2].

Unlike surgery, which physically removes the tumor, these medications travel through your bloodstream to reach tumor cells wherever they are [3]. They are designed to “silence the megaphone” of the disease by blocking the CSF1R receptor [4][1].

The Goals of Systemic Therapy

It is important to have realistic expectations. For most patients, these drugs are not a permanent “cure” that makes the disease disappear forever. Instead, the goals are:

  • Tumor Shrinkage: About 40% of patients see a significant reduction in the size of their tumor [5].
  • Symptom Relief: Most patients experience a decrease in pain and an improvement in how well they can move their joint [6][7].
  • Avoidance of Highly Destructive Surgery: These drugs can prevent the need for severe surgeries that might involve amputations or the loss of major nerves and blood vessels [2][8].

Comparing the Main Options

Currently, two primary targeted therapies are used for TGCT. Both work by inhibiting the CSF1 receptor, but they have different safety profiles.

Pexidartinib (Turalio)

Pexidartinib was the first systemic therapy approved for TGCT [9].

  • Efficacy: Approximately 39% of patients achieve an objective response (tumor shrinkage) [5].
  • The Black Box Warning: This medication carries a “black box” warning—the FDA’s most serious warning—due to the risk of severe and potentially fatal liver injury [10][11].
  • Monitoring (REMS): To use this drug, you and your doctor must enroll in the REMS (Risk Evaluation and Mitigation Strategy) program [11]. This involves mandatory, frequent blood tests to check your liver enzymes, especially during the first few months of treatment [10].

Vimseltinib

Vimseltinib is a newer, highly selective medication developed by Deciphera Pharmaceuticals that received recent FDA approval (late 2024) [12][5].

  • Efficacy: It has shown a similar response rate to pexidartinib, with about 40% of patients seeing tumor shrinkage [5][6].
  • Safety Profile: Early data suggests vimseltinib may have a better safety profile regarding the liver, with fewer cases of severe enzyme elevations compared to pexidartinib [5][13].
  • Side Effects: While it is generally well-tolerated, patients may experience side effects common to this class of drugs, such as periorbital edema (swelling around the eyes) or changes in hair color [12][14].

Pregnancy and Fertility Warnings

Because CSF1R inhibitors aggressively target biological pathways involved in cell growth, they can cause serious harm to a developing fetus [9]. Both male and female patients of reproductive age must use highly effective contraception during treatment and for a specific period after the last dose. Always discuss family planning with your oncologist before starting these drugs.

Clinical Trials and Other Options

The landscape of systemic therapy for TGCT is rapidly evolving. Because researchers are constantly looking for ways to target the CSF1 pathway with fewer side effects, many patients choose to participate in clinical trials. A clinical trial might offer access to the newest generation of inhibitors before they are widely available [8].

If clinical trials or the approved primary medications are not an option, some doctors may prescribe imatinib (Gleevec) off-label [15]. While not specifically approved for TGCT, imatinib has shown an ability to stabilize the disease and control symptoms in some patients [15][16].

When to Make the Switch

The decision to move from surgery to systemic therapy is a major milestone. Most specialists suggest this shift when:

  1. Surgery is Highly Destructive: Removing the tumor would require sacrificing a major nerve or blood vessel [2][17].
  2. Multiple Failures: The tumor has returned quickly after two or more well-performed surgeries [2][18].
  3. Extensive Disease: The tumor is so infiltrative that a surgeon knows they cannot clear enough of it to prevent a rapid recurrence [19][2].

Common questions in this guide

When is systemic therapy used for TGCT?
Systemic therapy is recommended when a tumor cannot be safely removed by surgery, has returned multiple times after previous operations, or if surgery would cause permanent disability or joint damage.
Will CSF1R inhibitors cure my TGCT completely?
For most patients, these medications are not a permanent cure. They are used to shrink the tumor, relieve joint pain, improve movement, and help avoid highly destructive surgeries.
What is the difference between pexidartinib and vimseltinib?
Both are targeted therapies with similar tumor shrinkage rates. However, pexidartinib carries a strict warning for severe liver injury and requires mandatory monitoring, while early data suggests vimseltinib may have a lower risk of severe liver side effects.
Do I need to use birth control while taking CSF1R inhibitors?
Yes. Because these drugs aggressively target cell growth pathways, they can cause serious harm to a developing fetus. Both male and female patients of reproductive age must use highly effective contraception during treatment and for a period afterward.
What is the REMS program for pexidartinib?
The Risk Evaluation and Mitigation Strategy (REMS) is a mandatory safety program for patients taking pexidartinib. It requires frequent blood tests, especially in the first few months, to closely monitor liver enzymes and prevent severe liver injury.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I considered unresectable, or would surgery for my TGCT cause unacceptable joint damage or disability?
  2. 2.What are the differences between pexidartinib and vimseltinib in terms of monitoring requirements and liver safety?
  3. 3.If I start a CSF1R inhibitor, what is the exit strategy—is this a long-term medication, or will we re-evaluate for surgery after the tumor shrinks?
  4. 4.How do these medications affect fertility, and what specific birth control protocols must I follow while taking them?
  5. 5.Are there any ongoing clinical trials for newer CSF1R inhibitors that I might qualify for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Medical Management of Tenosynovial Giant Cell Tumor.

    Palmerini E, Trent JC, Hornicek FJ

    Current oncology reports 2025; (27(7)):844-855 doi:10.1007/s11912-025-01679-x.

    PMID: 40392406
  2. 2

    Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease.

    Healey JH, Bernthal NM, van de Sande M

    Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews 2020; (4(11)):e20.00028 doi:10.5435/JAAOSGlobal-D-20-00028.

    PMID: 33156160
  3. 3

    Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.

    Tap WD, Gelderblom H, Palmerini E, et al.

    Lancet (London, England) 2019; (394(10197)):478-487 doi:10.1016/S0140-6736(19)30764-0.

    PMID: 31229240
  4. 4

    Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.

    Smith BD, Kaufman MD, Wise SC, et al.

    Molecular cancer therapeutics 2021; (20(11)):2098-2109 doi:10.1158/1535-7163.MCT-21-0361.

    PMID: 34433663
  5. 5

    Management of tenosynovial giant cell tumor: approved and investigational therapies.

    Conway AP, Lim A, Schulte BC, Agulnik M

    Expert review of anticancer therapy 2026; 1-9 doi:10.1080/14737140.2026.2620510.

    PMID: 41557367
  6. 6

    Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Gelderblom H, Bhadri V, Stacchiotti S, et al.

    Lancet (London, England) 2024; (403(10445)):2709-2719 doi:10.1016/S0140-6736(24)00885-7.

    PMID: 38843860
  7. 7

    Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.

    Van De Sande M, Tap WD, Gelhorn HL, et al.

    Acta orthopaedica 2021; (92(4)):493-499 doi:10.1080/17453674.2021.1922161.

    PMID: 33977825
  8. 8

    Pexidartinib Upfront in a Case of Tenosynovial Giant Cell Tumor: Proof of Concept for a Treatment Paradigm Shift.

    Palmerini E, Peta G, Tuzzato G

    Oncology and therapy 2024; (12(4)):833-841 doi:10.1007/s40487-024-00298-z.

    PMID: 39155359
  9. 9

    Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.

    Palmerini E, Longhi A, Donati DM, Staals EL

    Expert review of anticancer therapy 2020; (20(6)):441-445 doi:10.1080/14737140.2020.1757441.

    PMID: 32297819
  10. 10

    Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience.

    Dharmani C, Wang E, Salas M, et al.

    Future oncology (London, England) 2022; (18(13)):1595-1607 doi:10.2217/fon-2021-1475.

    PMID: 35105158
  11. 11

    TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) program: 5-year retrospective hepatic safety assessment.

    Waheed Rajper A, Dharmani C, Chilakapati L, et al.

    Future oncology (London, England) 2025; (21(15)):1859-1865 doi:10.1080/14796694.2025.2509409.

    PMID: 40438996
  12. 12

    CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.

    Gelderblom H, Razak AA, Taylor MH, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(18)):3996-4004 doi:10.1158/1078-0432.CCR-24-0103.

    PMID: 38995311
  13. 13

    Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs).

    Dou F, Lu D, Gao J

    Intractable & rare diseases research 2025; (14(2)):143-144 doi:10.5582/irdr.2025.01010.

    PMID: 40485889
  14. 14

    Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.

    Robert M, Farese H, Miossec P

    Frontiers in immunology 2022; (13()):820046 doi:10.3389/fimmu.2022.820046.

    PMID: 35265077
  15. 15

    Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.

    Spierenburg G, Grimison P, Chevreau C, et al.

    European journal of cancer (Oxford, England : 1990) 2022; (173()):219-228 doi:10.1016/j.ejca.2022.06.028.

    PMID: 35932628
  16. 16

    Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.

    Gelderblom H, Cropet C, Chevreau C, et al.

    The Lancet. Oncology 2018; (19(5)):639-648 doi:10.1016/S1470-2045(18)30143-8.

    PMID: 29571946
  17. 17

    ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT).

    Tap W

    Future oncology (London, England) 2020; (16(25)):1875-1878 doi:10.2217/fon-2020-0307.

    PMID: 32755241
  18. 18

    Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.

    Brahmi M, Vinceneux A, Cassier PA

    Current treatment options in oncology 2016; (17(2)):10 doi:10.1007/s11864-015-0385-x.

    PMID: 26820289
  19. 19

    Severity classification of Tenosynovial Giant Cell Tumours on MR imaging.

    Mastboom MJL, Verspoor FGM, Hanff DF, et al.

    Surgical oncology 2018; (27(3)):544-550 doi:10.1016/j.suronc.2018.07.002.

    PMID: 30217317

This page provides educational information about systemic therapies and CSF1R inhibitors for TGCT. Always consult your oncologist to determine if these medications are appropriate and safe for your specific condition.

Get notified when new evidence is published on Tenosynovial giant cell tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.